Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: OSE Immunotherapeutics [OSE] ::.

OSE Immunotherapeutics results from the merger of OSE Pharma and Effimune. The company specializes in immunotherapy. Their lead product, Tedopi, offers new perspectives in lung cancer management, particularly in Non-Small Cell Lung Cancer (NSCLC) that is resistant to chemotherapy and has a poor prognosis. Efficacy of Tedopi has already been demonstrated in a Phase II study, and the product is currently in an international Phase III clinical trial, whose results are expected in 2018. The second product is FR104, a Phase II-ready drug candidate for Rheumatoid Arthritis. Janssen could exercise an option to license FR104 in H2-2016.

The coverage was initiated June 24th, 2015

Our target price for Ose Immunotherapeutics as of June 27th, 2017, is €13.51/ share



OSE Pharma